Plain-English translation of NCT06760364 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study of a new medication called designed to treat advanced pancreatic cancer. The medication is delivered directly into arteries (blood vessels) feeding the cancer. Researchers will start with lower doses and carefully increase them to find the safest and most effective dose, while watching closely for side effects and how well the treatment works.
Advanced pancreatic cancer is very difficult to treat, and many patients don't respond well to standard chemotherapy or can't tolerate it. This trial is testing whether this new treatment approach—delivering medication directly to the tumor through blood vessels—might offer better results for patients whose tumors have the mesothelin marker.
You likely qualify if…
You likely don't qualify if…
You would receive through an arterial infusion—a small tube placed into a blood vessel that delivers the medication directly to your tumor. The trial starts with a small group of patients at a low dose, and if it is safe, the next group receives a slightly higher dose. Researchers will monitor you closely with blood tests, imaging scans, and clinic visits to watch for side effects and measure how your cancer responds to treatment.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Collaborators
Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
Enrollment target
~21 participants
Started
December 2024
Primary completion
December 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jihui Hao, Ph.D
Tianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.